VIDEO: Datopotamab deruxtecan appears 'quite active' in pretreated breast cancer subset
Click Here to Manage Email Alerts
In this video, Ian E. Krop, MD, PhD, associate chief of the division of breast oncology in the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, discusses results from the TROPION-PanTumor01 study.
He presented findings from the phase 1 study — which assessed datopotamab deruxtecan among patients with metastatic HER2-negative breast cancer — at this year’s San Antonio Breast Cancer Symposium.
“There has been a lot of progress made in the treatment of metastatic triple-negative breast cancer, but unfortunately for patients whose cancer has developed resistance to chemotherapy, the treatment options still are quite limited,” Krop said, adding that the TROP2 cell surface protein appears to be a promising target in triple-negative disease.
He said that the phase 1 trial previously showed the “optimal” dose was 6 mg/kg of datopotamab deruxtecan every 3 weeks, adding, “what we reported at [SABCS] this year was the expansion cohort of 44 patients with metastatic triple-negative breast cancer.”
Krop said those included in the expansion cohort were heavily pretreated, with a median of three previous therapies.
Despite being heavily pretreated, the patients had an overall response rate of 34%.
“Overall, this drug does look like it’s quite active with durable benefit in patients with pretreated triple-negative advanced breast cancer, and we do think that based on this data, that we should be exploring other studies of the agent [datopotamab deruxtecan] in triple-negative breast cancer and in other breast cancer subtypes.”
He added that multiple trials are underway or being developed to further evaluate datopotamab deruxtecan.
References:
- Krop IE, et al. Abstract GS1-05. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-10, 2021; San Antonio.
Collapse
Read more about
Click Here to Manage Email Alerts